Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.
A successful Mylan challenge would see generic entry within two years – though Biogen has fought off copycats before.
Of the five biggest products set to lose exclusivity in the US this year the Swiss pharma giant owns three: Avastin, Herceptin and Tarceva.
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
Vantage’s roundup of medtech news you might have missed includes Boston Scientific hitting its 11th biz dev deal of the year.
Celgene’s Revlimid ranks as biopharma’s most contested blockbuster, with a huge spread in future sales forecasts, while drugs from Bristol-Myers Squibb and Sanofi also…
Generic versions of Acorda’s Ampyra are about to flood the market, meaning that the company desperately needs a timely approval in October for its next big hope.
Medicare Advantage plans have been cleared to seek cheaper alternatives for biologicals beginning next year.
Drug price inflation has slowed to crawl, but political pressure can only keep a lid on costs for so long.